



## New Vaccine Technologies and Approaches 2.0

Guest Editors:

### Dr. Stephen A. Morris

The Future Vaccine  
Manufacturing Research Hub,  
Department of Biochemical  
Engineering, University College  
London, Bernard Katz Building,  
London WC1E 6BT, UK

### Dr. Camila Coelho

Laboratory of Malaria  
Immunology and Vaccinology,  
NIAID, NIH- Bethesda, MD, USA

Deadline for manuscript  
submissions:

**closed (15 December 2021)**

### Message from the Guest Editors

The urgent global need for vaccines to prevent COVID-19, allied with the rapid development of immunization approaches targeting SARS-CoV-2, evidences how the vaccinology field has substantially evolved lately. New technologies for antigen design, the rapid discovery of high neutralizing monoclonal antibodies and the development of new delivery platforms are only a few examples. In addition, in recent years, innumerable changes have occurred in terms of density, age and traveling habits of the world population. Thus, changes in vaccine development that can address all these issues need to be implemented.

This Special Issue aims to gather the latest research on new vaccine technologies and approaches, including, but not limited to, the following topics:

1. Adjuvants;
2. Antigen design;
3. Delivery platforms;
4. Nanoparticle viral vectors;
5. Vaccine development for outbreaks;
6. Immunization with whole organisms;
7. DNA vaccines;
8. RNA vaccines;
9. Genetic adjuvants.

We look forward to your contribution to this Special Issue!





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)